文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病消化内镜

upfront内镜检查在未调查的消化不良中最大化成本效益与成本满意度

Up-Front Endoscopy Maximizes Cost-Effectiveness and Cost-Satisfaction in Uninvestigated Dyspepsia.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-01-13

研究构建决策分析模型,对无警报症状的未调查消化不良患者比较四种策略在1年内的成本、满意度和健康产出。结果显示患者视角下各策略成本与结局相似, upfront内镜最大化成本满意度和卫生系统报销,检测幽门螺杆菌阳性后内镜策略最大化保险方与患者视角的成本效益。作者认为非侵入性管理策略的成本效益和患者满意度可能劣于 upfront内镜策略。

要点

  • 患者视角下四种策略自付费用差异最大30美元,健康产出差异小于0.01质量调整生命年/年。
  • upfront内镜最大化成本满意度和卫生系统报销。
  • 检测幽门螺杆菌阳性后内镜策略最大化保险方和患者视角的成本效益。

核心结论

  • 非侵入性管理策略在成本效益和患者满意度方面似乎劣于促进 upfront内镜的策略。
  • 需要额外研究评估患者满意度的驱动因素,以促进纳入价值医疗转型工作。

研究设计与样本

  • 构建决策分析模型,进行为期1年的成本效益/成本满意度分析。
  • 对象为转诊至消化科的無警报症状的未调查消化不良患者。
  • RAND/UCLA专家小组参与模型设计。
  • 评估四种竞争性诊断/管理策略: upfront内镜、检测幽门螺杆菌阳性即根除(检测与治疗)、检测幽门螺杆菌阳性即内镜(检测与内镜)、经验性抑酸。
  • 结局来自临床试验的系统综述;成本来自前瞻性观察队列研究和国家商业/联邦成本数据库;健康获益用质量调整生命年表示。

主要发现

  • 患者视角下,所有策略的成本和结局相似,自付费用最大差异为30美元,每年获得的质量调整生命年差异小于0.01,无论采用何种策略。
  • upfront内镜最大化成本满意度和卫生系统报销。
  • 检测与内镜策略最大化保险方和患者视角的成本效益。
  • 结果在模型输入的多个单因素敏感性分析和大多数支付意愿阈值下保持稳健。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要额外研究评估患者满意度的驱动因素,以促进纳入价值医疗转型工作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Practice guidelines promote a routine noninvasive, non-endoscopic initial approach to investigating dyspepsia without alarm features in young patients, yet many patients undergo prompt upper endoscopy. We aimed to assess tradeoffs among costs, patient satisfaction, and clinical outcomes to inform discrepancy between guidelines and practice. METHODS: We constructed a decision-analytic model and performed cost-effectiveness/cost-satisfaction analysis over a 1-year time horizon on patients with uninvestigated dyspepsia without alarm features referred to gastroenterology. A RAND/UCLA expert panel informed model design. Four competing diagnostic/management strategies were evaluated: prompt endoscopy, testing for Helicobacter pylori and eradicating if present (test-and-treat), testing for H pylori and performing endoscopy if present (test-and-scope), and empiric acid suppression. Outcomes were derived from systematic reviews of clinical trials. Costs were informed by prospective observational cohort studies and national commercial/federal cost databases. Health gains were represented using quality-adjusted life years. RESULTS: From the patient perspective, costs and outcomes were similar for all strategies (maximum out-of-pocket difference of $30 and <0.01 quality-adjusted life years gained/year regardless of strategy). Prompt endoscopy maximized cost-satisfaction and health system reimbursement. Test-and-scope maximized cost-effectiveness from insurer and patient perspectives. Results remained robust on multiple one-way sensitivity analyses on model inputs and across most willingness-to-pay thresholds. CONCLUSIONS: Noninvasive management strategies appear to result in inferior cost-effectiveness and patient satisfaction outcomes compared with strategies promoting up-front endoscopy. Therefore, additional studies are needed to evaluate the drivers of patient satisfaction to facilitate inclusion in value-based healthcare transformation efforts.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wechsler EV, Ahuja NK, Brenner D, et al. Up-Front Endoscopy Maximizes Cost-Effectiveness and Cost-Satisfaction in Uninvestigated Dyspepsia. Clin Gastroenterol Hepatol. 2023. PMID: 36646234. doi:10.1016/j.cgh.2023.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。